Lancet Psychiatry最新文献

筛选
英文 中文
Are you suicidal? 你想自杀吗?
IF 21.1 1区 医学
Lancet Psychiatry Pub Date : 2026-10-01 Epub Date: 2026-05-22 DOI: 10.1016/S2215-0366(26)00157-4
Name Address Supplied
{"title":"Are you suicidal?","authors":"Name Address Supplied","doi":"10.1016/S2215-0366(26)00157-4","DOIUrl":"10.1016/S2215-0366(26)00157-4","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":"826-827"},"PeriodicalIF":21.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147989577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relapse trajectories and antipsychotic discontinuation in schizophrenia from individual participant data of five trials from the Yale Open Data Access database: a meta-analysis. 来自耶鲁大学开放数据访问数据库的五项试验的个体参与者数据:精神分裂症的复发轨迹和抗精神病药物停药:一项荟萃分析
IF 21.1 1区 医学
Lancet Psychiatry Pub Date : 2026-10-01 Epub Date: 2026-08-24 DOI: 10.1016/S2215-0366(26)00225-7
Krisya Louie, Sameer Jauhar, Jose Rubio, Bodyl Brand, Toby Pillinger, Oliver D Howes, Robert A McCutcheon
{"title":"Relapse trajectories and antipsychotic discontinuation in schizophrenia from individual participant data of five trials from the Yale Open Data Access database: a meta-analysis.","authors":"Krisya Louie, Sameer Jauhar, Jose Rubio, Bodyl Brand, Toby Pillinger, Oliver D Howes, Robert A McCutcheon","doi":"10.1016/S2215-0366(26)00225-7","DOIUrl":"10.1016/S2215-0366(26)00225-7","url":null,"abstract":"<p><strong>Background: </strong>Antipsychotics reduce risk of relapse in schizophrenia, but longer-term use is associated with adverse effects, often prompting dose reduction or discontinuation. Although discontinuation increases relapse risk, the clinical course is heterogeneous. Rapid relapse following antipsychotic discontinuation has been observed in clinical trials and could reflect a direct pharmacological consequence of stopping medication, as opposed to re-emergence of underlying illness. We aimed to identify distinct trajectories of symptom change preceding relapse, to examine whether trajectory membership was associated with treatment arm and baseline clinical characteristics, and to compare symptom profiles at time of relapse between individuals whose illness relapsed following discontinuation and those whose illness relapsed during continued treatment.</p><p><strong>Methods: </strong>For this meta-analysis, on May 4, 2025, we searched the Yale University Open Data Access project database for randomised, double-blind, discontinuation trials of antipsychotics in individuals with schizophrenia or schizoaffective disorder. No language restrictions were applied. We included double-blind, placebo-controlled, relapse-prevention, randomised trials of antipsychotic medications. Studies with available individual participant data were included if participants were first treated with antipsychotic drugs for more than 3 months and clinically stabilised before they were randomly assigned to placebo (discontinuation) or continued active treatment. We excluded studies that involved diagnoses other than schizophrenia or schizoaffective disorder. We analysed longitudinal symptom data (using the Positive and Negative Syndrome Scale [PANSS]) from individuals whose illness relapsed. Latent class mixed modelling identified distinct trajectories of symptom change preceding relapse. We first examined associations between trajectory membership and treatment discontinuation or continuation. We then compared symptom profiles at both baseline and point of relapse, between both trajectory groups and discontinuation status. The study was not preregistered; the Yale University Open Data Access project ID is 2025-0740.</p><p><strong>Findings: </strong>We identified five randomised, double-blind, placebo-controlled, discontinuation trials of oral and long-acting injectable (LAI) paliperidone. In our analysis, we included 271 participants from the LAI trials (155 men [57%] and 116 women [43%], mean age 38·4 years [SD 11·2, range 18-65]) and 146 from the oral trials (72 men [49%] and 74 women [51%], mean age 34·8 years [SD 11·5, range 18-61]). Two latent classes of relapse were identified: rapid and delayed onset, with rapid relapse associated with more severe symptoms at point of relapse. The proportion with rapid relapse did not differ between continuation and discontinuation groups in either LAI (discontinuation 39 [20%] of 197, continuation eight [11%] of 74; p=0·1","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":"829-840"},"PeriodicalIF":21.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148814661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relapse or rebound: the case for personalisation in antipsychotic discontinuation. 复发或反弹:抗精神病药物停药个体化的案例。
IF 21.1 1区 医学
Lancet Psychiatry Pub Date : 2026-10-01 Epub Date: 2026-08-24 DOI: 10.1016/S2215-0366(26)00270-1
Rajeev Krishnadas, C A Smitha
{"title":"Relapse or rebound: the case for personalisation in antipsychotic discontinuation.","authors":"Rajeev Krishnadas, C A Smitha","doi":"10.1016/S2215-0366(26)00270-1","DOIUrl":"10.1016/S2215-0366(26)00270-1","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":"812-813"},"PeriodicalIF":21.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148814608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From discovery to proof: a Translation Evidence Map for precision psychiatry 从发现到证明:精确精神病学的翻译证据图
IF 64.3 1区 医学
Lancet Psychiatry Pub Date : 2026-10-01 DOI: 10.1016/s2215-0366(26)00267-1
Bernhard T Baune
{"title":"From discovery to proof: a Translation Evidence Map for precision psychiatry","authors":"Bernhard T Baune","doi":"10.1016/s2215-0366(26)00267-1","DOIUrl":"https://doi.org/10.1016/s2215-0366(26)00267-1","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"15 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Open Dialogue versus treatment as usual for adults presenting in crisis to mental health services in England (the ODDESSI Trial): a multisite cluster-randomised trial. 英国心理健康服务中出现危机的成年人的公开对话与常规治疗(ODDESSI试验):一项多地点集群随机试验。
IF 21.1 1区 医学
Lancet Psychiatry Pub Date : 2026-10-01 Epub Date: 2026-08-26 DOI: 10.1016/S2215-0366(26)00229-4
Stephen Pilling, Thomas Craig, Katherine Clarke, Petrina Chu, Kirsty James, Jaakko Seikkula, Manuel Gomes, Jiunn Wang, Emma Mckenzie, Nicole Sze Chi Chan, Tom Cant, Sarah Carr, Victoria Clark, Joanna Curwen, Corrine Hendy, Mark Hopfenbeck, Yasmin Ishaq, Gareth Jarvis, Amy Jebreel, Jahara Khatun, Catherine Kinane, Sarah Noordally, Shaeda Nourmand, James Osborne, Georgie Parker, Daniel Scott, Jerry Tew, Sonia Johnson, Douglas Ziedonis, Timothy Weaver, Sabine Landau, Russell Razzaque
{"title":"Open Dialogue versus treatment as usual for adults presenting in crisis to mental health services in England (the ODDESSI Trial): a multisite cluster-randomised trial.","authors":"Stephen Pilling, Thomas Craig, Katherine Clarke, Petrina Chu, Kirsty James, Jaakko Seikkula, Manuel Gomes, Jiunn Wang, Emma Mckenzie, Nicole Sze Chi Chan, Tom Cant, Sarah Carr, Victoria Clark, Joanna Curwen, Corrine Hendy, Mark Hopfenbeck, Yasmin Ishaq, Gareth Jarvis, Amy Jebreel, Jahara Khatun, Catherine Kinane, Sarah Noordally, Shaeda Nourmand, James Osborne, Georgie Parker, Daniel Scott, Jerry Tew, Sonia Johnson, Douglas Ziedonis, Timothy Weaver, Sabine Landau, Russell Razzaque","doi":"10.1016/S2215-0366(26)00229-4","DOIUrl":"10.1016/S2215-0366(26)00229-4","url":null,"abstract":"<p><strong>Background: </strong>Open Dialogue is a person-centred, transdiagnostic model of mental health care that emphasises continuity, therapeutic relationships, and collaboration with the service user's social network. Open Dialogue is a service-wide approach to care involving network meetings with the service user, members of their social network, and usually two practitioners who support the network throughout the duration of care. In this cluster-randomised trial, we aimed to evaluate the clinical effectiveness of Open Dialogue versus treatment as usual for adults presenting in crisis to community mental health services in England.</p><p><strong>Methods: </strong>This multicentre, parallel two-arm, cluster-randomised, controlled superiority trial was conducted in mental health services in five National Health Service trusts in London and the South of England. Clusters were defined at the level of primary care practices within service catchment areas. Participants were adults aged 18 years or older presenting in crisis to mental health services and registered with a practice within trial clusters. Randomisation was done at the cluster level (1:1), stratified by catchment area, and balanced on average general practice (GP) list size and Index of Multiple Deprivation (2015). The chief investigator, senior statistician, and assessors of the primary outcome were masked in the study. Participants either received Open Dialogue or treatment as usual, which refers to the functional team model currently implemented throughout English mental health services. The primary outcome was time (days) to first relapse following initial recovery from the index crisis censored at the end of the 2-year follow-up period. Participant-reported secondary outcomes were EuroQol Visual Analogue Scale, Social Provisions Scale, Lubben Social Network Scale, Questionnaire about the Process of Recovery, and the Client Satisfaction Questionnaire, measured at five timepoints over 2 years, and clinical measures were extracted from electronic health records. People with relevant lived experience were involved in the design and execution of the study. Fidelity to the model of care in Open Dialogue and treatment as usual, and adherence to the delivery of Open Dialogue, were measured prior to each site starting participant recruitment, then every 6 months thereafter until the final participant follow-up in that site. The trial was retrospectively registered (ISRCTN52653325) and is complete.</p><p><strong>Findings: </strong>185 general practices associated with six mental health Trusts across England were identified for screening. 105 practices were excluded, and 80 were included in cluster formation, forming 32 clusters that were randomly assigned (16 to treatment as usual and 16 to the Open Dialogue intervention). One mental health trust (two clusters) withdrew, resulting in five mental health trusts (30 clusters) participating in the trial. Between June 25, 2019, and Dec 9, 20","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":"841-851"},"PeriodicalIF":21.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148833844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and the UK. CYP2D6和CYP2C19基因型与文拉法辛治疗失败的关系:来自挪威和英国的两个队列的回顾性研究
IF 21.1 1区 医学
Lancet Psychiatry Pub Date : 2026-10-01 DOI: 10.1016/S2215-0366(26)00238-5
Yoomi Park, Hasan Çağın Lenk, Yitian Zhou, Volker M Lauschke, Espen Molden
{"title":"Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and the UK.","authors":"Yoomi Park, Hasan Çağın Lenk, Yitian Zhou, Volker M Lauschke, Espen Molden","doi":"10.1016/S2215-0366(26)00238-5","DOIUrl":"10.1016/S2215-0366(26)00238-5","url":null,"abstract":"<p><strong>Background: </strong>Venlafaxine shows superior efficacy over SSRIs in treating major depression. Metabolism of venlafaxine is mediated by CYP2D6 with a secondary role of CYP2C19. The activity of both enzymes is determined by pharmacogenetic variability, which might affect therapeutic response to venlafaxine. We aimed to investigate associations between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure.</p><p><strong>Methods: </strong>This retrospective, observational study included two independent, naturalistic cohorts of individuals treated with venlafaxine from the Center for Psychopharmacology (Oslo, Norway) and the UK Biobank. Participants were excluded if they were comedicated with strong CYP2D6 or CYP2C19 inhibitors (ie, bupropion, fluoxetine, paroxetine, fluvoxamine, or levomepromazine) or CYP inducers (ie, carbamazepine, phenobarbital, or phenytoin) at their last venlafaxine therapeutic drug monitoring measurement. Participants were stratified into genotype-predicted poor metabolisers (PMs), intermediate metabolisers (IMs), normal metabolisers (NMs), and ultra-rapid metabolisers (UMs). The primary outcome was treatment failure defined as switching away from venlafaxine to another antidepressant within 1 year after last exposure. People with lived experience did not contribute to the design and writing of this study.</p><p><strong>Findings: </strong>Between Jan 1, 2005, and Dec 15, 2025, 5443 participants genotyped for CYP2D6 and CYP2C19 (3315 [60·9%] women, 2128 [39·1%] men; mean age 48·9 years [SD 18·6]) were identified from the Center for Psychopharmacology. 3624 participants (2401 [66·3%] women, 1223 [33·7%] men; mean age 56·5 years [SD 9·8]) with prescription data were identified from the UK Biobank between 2006 and 2010. In the Norwegian cohort, odds of switching were 2·05 times higher in CYP2D6 PMs (95% CI 1·53-2·71, p<0·0001), 1·25 times higher in IMs (1·05-1·50, p=0·014), and 1·78 times higher in UMs (1·06-2·83, p=0·021) compared with NMs. Increased odds of switching in CYP2D6 PMs were also shown in the UK Biobank cohort (odds ratio 1·58 [95% CI 1·14-2·19], p=0·0060). CYP2C19 PM status amplified risk of failure in the Norwegian cohort with 6·11 times higher odds of switching in dual PMs versus NMs (95% CI 1·81-18·77, p=0·0019).</p><p><strong>Interpretation: </strong>CYP2D6 PM status was consistently associated with increased risk of venlafaxine treatment failure in two large, real-life cohorts, suggesting that pre-emptive genotyping could facilitate personalised venlafaxine therapy.</p><p><strong>Funding: </strong>European Research Council, Swedish Research Council, Novo Nordisk Foundation, Robert Bosch Foundation, National Research Foundation of Korea, and the South-Eastern Norway Regional Health Authority.</p>","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"13 10","pages":"852-860"},"PeriodicalIF":21.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148921381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Harnessing the Venezuelan diaspora for safe mental health and psychosocial support after the 2026 earthquakes. 在2026年地震后,利用委内瑞拉侨民获得安全的精神健康和社会心理支持。
IF 21.1 1区 医学
Lancet Psychiatry Pub Date : 2026-10-01 Epub Date: 2026-08-05 DOI: 10.1016/S2215-0366(26)00231-2
Maria Alejandra Pulido Febres, Milton L Wainberg, Lilian Abbo, Nurys Morin Cabrera, Zelde Espinel, James M Shultz
{"title":"Harnessing the Venezuelan diaspora for safe mental health and psychosocial support after the 2026 earthquakes.","authors":"Maria Alejandra Pulido Febres, Milton L Wainberg, Lilian Abbo, Nurys Morin Cabrera, Zelde Espinel, James M Shultz","doi":"10.1016/S2215-0366(26)00231-2","DOIUrl":"10.1016/S2215-0366(26)00231-2","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":"822-824"},"PeriodicalIF":21.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148680675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From prediction to decision: prediction-based decision rules and target trial emulation in ADHD. 从预测到决策:ADHD中基于预测的决策规则和目标试验模拟。
IF 21.1 1区 医学
Lancet Psychiatry Pub Date : 2026-10-01 Epub Date: 2026-08-20 DOI: 10.1016/S2215-0366(26)00227-0
Miguel Garcia-Argibay, Stephen V Faraone, Zheng Chang, Samuele Cortese, Henrik Larsson
{"title":"From prediction to decision: prediction-based decision rules and target trial emulation in ADHD.","authors":"Miguel Garcia-Argibay, Stephen V Faraone, Zheng Chang, Samuele Cortese, Henrik Larsson","doi":"10.1016/S2215-0366(26)00227-0","DOIUrl":"10.1016/S2215-0366(26)00227-0","url":null,"abstract":"<p><p>More than 100 prediction models have been developed to support the diagnosis, prognosis, or treatment of ADHD, yet none has reached routine clinical practice. In this Personal View, we argue that an important reason for this implementation gap is the absence of clearly defined prediction-based decision rules-formalised mappings from a model's output to specific clinical actions. Most published models report discrimination metrics such as the area under the receiver-operating-characteristic curve, but do not specify what a clinician should do differently for a patient classified as at high risk versus low risk. Without this link to action, even an accurate model remains clinically inert. We describe how prediction-based decision rules, combined with target trial emulation of their clinical utility in large observational datasets, offer a feasible path forward. We illustrate the approach with two worked ADHD examples (treatment intensity guided by predicted persistence and medication selection guided by predicted treatment response) and propose four priorities to shift the field from model development towards decision-oriented evaluation and implementation.</p>","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":"897-904"},"PeriodicalIF":21.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148800024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Psychiatry 2026; 13: 783-91. 《柳叶刀精神病学》2026修订版;13: 783 - 91。
IF 21.1 1区 医学
Lancet Psychiatry Pub Date : 2026-10-01 Epub Date: 2026-08-19 DOI: 10.1016/S2215-0366(26)00264-6
{"title":"Correction to Lancet Psychiatry 2026; 13: 783-91.","authors":"","doi":"10.1016/S2215-0366(26)00264-6","DOIUrl":"10.1016/S2215-0366(26)00264-6","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":" ","pages":"e13"},"PeriodicalIF":21.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148800006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex differences in the efficacy, acceptability, and tolerability of antipsychotics in people with acute schizophrenia: individual participant data pairwise, dose–response, and network meta-analyses 急性精神分裂症患者抗精神病药物的疗效、可接受性和耐受性的性别差异:个体参与者数据成对、剂量反应和网络荟萃分析
IF 64.3 1区 医学
Lancet Psychiatry Pub Date : 2026-09-30 DOI: 10.1016/s2215-0366(26)00280-4
Yuki Furukawa MD, Spyridon Siafis MD, Johannes Schneider-Thoma MD, Nobuyuki Nomura PhD, Natalia E Fares-Otero PhD, Susan Illing MSc, Bram W C Storosum MD, Jasper B Zantvoord PhD, Georgios Schoretsanitis PhD, Christian Schwarz, Julia Schulz, Horst Naiser, Karl Heinz Möhrmann, Prof Josef Priller MD, Prof John M Davis MD, Prof Iris E Sommer PhD, Prof Orestis Efthimiou PhD, Prof Georgia Salanti PhD, Prof Stefan Leucht MD
{"title":"Sex differences in the efficacy, acceptability, and tolerability of antipsychotics in people with acute schizophrenia: individual participant data pairwise, dose–response, and network meta-analyses","authors":"Yuki Furukawa MD, Spyridon Siafis MD, Johannes Schneider-Thoma MD, Nobuyuki Nomura PhD, Natalia E Fares-Otero PhD, Susan Illing MSc, Bram W C Storosum MD, Jasper B Zantvoord PhD, Georgios Schoretsanitis PhD, Christian Schwarz, Julia Schulz, Horst Naiser, Karl Heinz Möhrmann, Prof Josef Priller MD, Prof John M Davis MD, Prof Iris E Sommer PhD, Prof Orestis Efthimiou PhD, Prof Georgia Salanti PhD, Prof Stefan Leucht MD","doi":"10.1016/s2215-0366(26)00280-4","DOIUrl":"https://doi.org/10.1016/s2215-0366(26)00280-4","url":null,"abstract":"Antipsychotics are the mainstay of schizophrenia treatment, but their efficacy and tolerability might differ between females and males, and previous evidence on sex differences has been inconsistent and methodologically limited. We aimed to evaluate sex differences in the efficacy, acceptability, and tolerability of antipsychotics in adults with acute schizophrenia.","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":"70 1","pages":""},"PeriodicalIF":64.3,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书